Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (Delstrigo®)

Assessment Status Rapid review complete
Drug Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate
Brand Delstrigo®
Indication For the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, lamivudine or tenofovir
Assessment Process
Rapid review commissioned 06/12/2018
Rapid review completed 16/01/2019
Rapid review outcome A full HTA is not recommended. The NCPE recommends that Destrigo® be considered for reimbursement.*

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement; February 2019